We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Integrated LC-MS System to Be Released in Conjunction with AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
What may be the first truly integrated sample preparation system for LC-MS (liquid chromatography-mass spectrometry) that allows users to process samples in an instrument that is directly attached to the LC-MS system is to be released at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Shimadzu Scientific Instruments (Kyoto, Japan) had announced that the release of the Clinical Laboratory Automation Module-2000 (CLAM-2000), a fully integrated sample pretreatment module for LC-MS, will coincide with the 2016 AACC Annual Meeting.

The CLAM-2000 system, which is on display in Booth 4054 of the expo, automatically performs all the processes necessary for analyzing blood and other biological samples, from scanning in information from the blood collection tubes to sample pretreatment and LC-MS analysis. More...
The for-research-use-only instrument is the first truly integrated sample preparation system for LC-MS. It allows users to process samples in an instrument that is directly attached to the LC-MS system, a simple and safe way for lab personnel to process and analyze samples.

The instrument is controlled by a user-friendly interface that offers a variety of functions that regulate reagent management, calibration curve management, control management, and system maintenance management. By automating operations such as dispensing, stirring, filtering, heating, and sample transfer, the system effectively improves data accuracy and achieves the high level of reproducibility needed for clinical research.

“This system highlights the considerable progress made in the use of mass spectrometers for high-sensitivity detection in medical R&D,” said Dr. Scott Kuzdzal, general manager of marketing at Shimadzu Scientific Instruments. “It is ideal for medical research centers, university medical departments, hospital pharmaceutical departments, and contract research organizations that are dealing with issues of variability in analytical results or laboratory efficiency. It can also effectively support forensic applications conducted by universities, research institutes, and testing companies.”

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Shimadzu Scientific Instruments

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.